CNTA Form 144: Option Exercise and Proposed Sale of 24,792 Shares

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (CNTA) reported a Form 144 notice showing an insider sale tied to a same-day option exercise. The filer intends to sell 24,792 shares of common stock on 09/09/2025 through UBS Financial Services (11 Madison Ave., New York) on the NASDAQ, with an aggregate market value of $495,840.00. The filing lists total shares outstanding as 134,073,436. The acquisition details state the shares were acquired by exercise of a stock option on 09/09/2025 and paid for in cash. The form indicates there were no securities sold by the reporting person in the past three months.

Insights

Financial Analyst

TL;DR: Insider exercised options and plans to sell 24,792 CNTA shares worth $495,840 on 09/09/2025; transaction disclosed per Rule 144.

The filing documents a routine Rule 144 notification: options were exercised and the resulting shares are to be sold through UBS on NASDAQ on the stated date. The disclosure includes the number of shares outstanding (134,073,436) and confirms no other sales in the prior three months by the reporting person. This is a compliance-focused disclosure rather than an earnings or operational event; it provides transparency about insider liquidity.

Compliance/Risk Analyst

TL;DR: Form 144 correctly details the proposed sale and acquisition method, meeting Rule 144 disclosure requirements.

The notice specifies the nature of acquisition (exercise of stock option), payment method (cash), broker (UBS Financial Services), sale date (09/09/2025), and aggregate market value ($495,840.00). The filer's representation that there is no undisclosed material adverse information is included in the form. The document appears to be a standard, complete Rule 144 filing based on the provided fields.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave. 4th Floor New York NY 10010	24792	495840.00	134073436	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2025	Exercise of Stock Option	Issuer			24792	09/09/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider transaction does the Centessa (CNTA) Form 144 disclose?

The Form 144 discloses an insider who exercised stock options and plans to sell 24,792 common shares on 09/09/2025 through UBS on NASDAQ.

How much are the shares being sold worth according to the filing?

The aggregate market value reported is $495,840.00 for the 24,792 shares.

What acquisition method is listed for the shares in the Form 144?

The shares were acquired by exercise of a stock option on 09/09/2025, with payment in cash.

Does the filing report any securities sold by the reporting person in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

How many shares outstanding does the Form 144 show for the issuer?

The form lists 134,073,436 shares outstanding.